Private Equity
Cambridge, Massachusetts-based Unum Therapeutics Inc, a developer of antibody-directed cellular immunotherapy, has raised $69.2 million for its IPO after pricing its 5.77 million shares at $12 per share. The stock began trading March 29, 2018 on the NASDAQ under the ticker symbol "UMRX." Morgan Stanley and Cowen are the lead underwriters. Unum's pre-IPO backers include New Leaf Venture Partners, Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures.
2 min read · 29 March 2018
Dayton, Ohio-based CSafe Global, a provider of cold chain packaging solutions for biopharmaceutical and life science companies, airlines and freight forwarders, has named Jeff Pepperworth as its new CEO. Previously, Pepperworth worked at Inmar Inc where he was president of the healthcare division. CSafe is a portfolio company of Thomas H. Lee Partners.
5 min read · 28 March 2018
Bedford, Massachusetts-based Homology Medicines Inc, a genetic medicines company, has raised $144 million for its IPO after pricing its 9 million shares at $16 per share. The stock began trading March 28, 2018 on the NASDAQ under the ticker symbol "FIXX." BofA Merrill Lynch, Cowen and Evercore ISI are the lead underwriters. Homology's pre-IPO backers include Deerfield Management, Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital, Alexandria Venture Investments, 5AM Ventures, ARCH Venture Partners and Temasek.
2 min read · 28 March 2018
3 min read · 27 March 2018
Thompson Street Capital Partners has agreed to acquire YX Genomics Holding Corp, the holding company of Memphis-based Transnetyx, an automated genotyping company for biomedical researchers. No financial terms were disclosed.
2 min read · 27 March 2018
J.W. Childs Associates is providing growth funding to A4, an Ann Arbor, Michigan-based provider of anesthesia and pain management services. As part of the transaction, J.W. Childs will merge A4 with portfolio company Siromed, a provider of anesthesiology physician services to hospitals, ASCs and other healthcare facilities. No financial terms were disclosed. Houlihan Lokey and Sheppard Mullin advised A4 on the deal while McDermott Will & Emery advised J.W. Childs and Siromed.
3 min read · 27 March 2018
UK-based Mereo BioPharma Group plc, a specialty biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the pricing terms have yet to be set. Mereo BioPharma plans on listing the stock on the NASDAQ under the ticker symbol "MREO." Cowen and Company LLC, BMO Capital Markets Corp and RBC Capital Markets LLC are the lead underwriters. Mereo's backers include Woodford Investment Management and Invesco.
3 min read · 26 March 2018
Ardian has agreed to sell Groupe Bio7, a French clinical pathology company, to Cerba HealthCare. No financial terms were disclosed.
4 min read · 26 March 2018
Ampersand Capital Partners has made an investment in MedPharm, a developer of topical and transdermal products for drug developers. No financial terms were disclosed.
3 min read · 26 March 2018
Brite Media Group, which is backed by The Beekman Group, has acquired New York City-based Mesmerize Marketing, a point-of-care media company focused on educating health-conscious consumers. No financial terms were disclosed.
4 min read · 26 March 2018
